Abstract:Abstract Abstract 4529 Engraftment failure is a rare but life-threatening complication of hematopoietic stem cell transplantation. The treatment of this condition is often challenging. We firstly reported haploidentical donor stem cells transplantation resulted in hematological reconstitution and long-time disease-free survival in a patient who developed engraftment failure after unrelated donor allogeneic stem cell transplantation and failure rescue treatment by re-infusion of autologous “back-up” stem cells. The 39-years-old male patient with acute myeloid leukemia(AML)-M2a achieved complete remission (CR) after one course of induction chemotherapy. He entered a lasting CR with 7 courses post-remission consolidation therapy and decided to receive unrelated donor allogeniec stem cell transplantation. In case of engraftment failure after allo-HSCT, autologous “back-up” cells were harvested after the last course chemotherapy (IDA 15 mg on days 1–2, 10 mg on day 3, Ara-c 300 mg on days 1–3, 200 mg on day 4), and mobilized with G-CSF 5 mg/kg/day for 5 days. The “back-up” cells consisting of 9.94×106/kg CD34+ cells were cryopreservated in liquid nitrogen. Fifteen months after de novo AML, the patient received a myeloablative conditioning regimen of busulfan and cyclophosphamide (busulfan 3.2 mg/kg/day on days -7 to -4, and cyclophosphamide 60 mg/kg/day on days -3 to -2), and an infusion of unrelated allogeneic peripheral stem cells from the Chinese Marrow Donor Program with a HLA-Cw allele mismatch on day 0. The graft contained 11.07×108/kg nucleated cells and 6.35×106/kg CD34+ cells. Pancytopenia was continuously observed during 28 days after transplantation and short tandem repeat-polymerase chain reaction (STR-PCR) analysis showed no donor chimera. As a rescue attempt for graft failure, cryopreservated autologous cells were re-infused on day +28. Unfortunately, pancytopenia was still continuously observed during 23 days after re-infused of “back-up” cells(51 days after unrelated transplantation), and bone marrow examination revealed severe bone marrow hypoplasia. On day +57 and +58 after unrelated transplantation, bone marrow cells containing 2.1×106/kg CD34+ stem cells and peripheral blood cells containing 2.81×106/kg CD34+ stem cells from a haploidentical donor sister (HLA matched in 5/10 alleles by high-resolution genotyping) were infused respectively after reduced-intensity conditioning with fludarabine and ATG (fludarabine 30mg/m2/d on day -5 to -1, ATG 100mg/d on day -4 to -1). Absolute neutrophil count >0.5×109/L was documented on day 12 after haploidentical transplantation. He achieved platelets count >20×109/L on day 28 after haploidentical transplantation. Twenty-nine days after haploidentical transplantation, bone marrow examination showed reconstitution and STR-PCR analysis indicated complete donor chimera. No grades III -IV aGVHD, extensive chronic GVHD, and severe infection after transplantation were observed. Recurrent bone marrow aspiration examinations showed the patient had been in CR. The patient remained alive during a 18-month follow-up after haploidentical transplantation. Our experience suggests that combined haploidentical donor BM and PBSC transplantation after Flu- and ATG-based conditioning could provide an effective therapeutic strategy for engraftment failure after unrelated allo-HSCT in adult patients. Considering the accessibility of haploidentical donors, haploidentical transplantation has the potential to act as a first-line choice for salvage therapy. Disclosures: No relevant conflicts of interest to declare.

Allogeneic Peripheral Blood Stem Cell Transplantation for Leukemia

Hla-Haploidentical Stem Cell Transplantation for Malignant Hematological Diseases Using G-Csf Mobilized Bone Marrow and Peripheral Blood Stem Cells

[Clinical Observation of Gleevec Combined with Myeloablative Allogeneic Stem Cells Transplantation in Treatment of Chronic Myeloid Leukemia].

Unrelated Donor Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in First Complete Remission.

[Allogeneic Peripheral Blood Stem Cell Transplantation in the Treatment of Hematologic Malignancies].

Treatment of Childhood Leukemia with Unrelated Donor Allogeneic Bone Marrow Tran Splantation

HLA-identical Sibling Allogeneic Peripheral Blood Stem Cell Transplantation in the Treatment of Acute Leukemia

Haploidentical Allogeneic Hematopoietic Cell Transplantation As Salvage Therapy for Engraftment Failure after Unrelated and Autologous Cell Transplantation.

Allogeneic peripheral blood stem cell transplantation for 75 cases of hematologic malignancies]

Long-term Outcome of Allogeneic Human Leukocyte Antigen-Matched Sibling-Donor Peripheral Blood Stem Cell Transplantation in Leukaemia Patients.

The Inferiority of G-PB to Rhg-Csf-mobilized Blood and Marrow Grafts As a Stem Cell Source in Patients with High-Risk Acute Leukemia Who Underwent Unmanipulated HLA-mismatched/haploidentical Transplantation: a Comparative Analysis

Improved outcomes using G-CSF-mobilized blood and bone marrow grafts as the source of stem cells compared with G-PB after HLA-identical sibling transplantation in patients with acute leukemia.

Analysis of 66 Cases Received Hematopoietic Stem Cell Transplantation from Unrelated Donors

Improved outcomes using <scp>G‐CSF</scp>‐mobilized blood and bone marrow grafts as the source of stem cells compared with <scp>G‐PB</scp> after <scp>HLA</scp>‐identical sibling transplantation in patients with acute leukemia

Efficacy and Safety of Unmanipulated Haploidentical Related Donor Allogeneic Peripheral Blood Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Peripheral Blood Stem Cell Transplantation from Haploidentical Related Donor Could Achieve Satisfactory Clinical Outcomes for Intermediate- or High-Risk Adult Acute Myeloid Leukemia Patients.

G-CSF-Primed Peripheral Blood Stem Cell Haploidentical Transplantation Could Achieve Satisfactory Clinical Outcomes for Acute Leukemia Patients in the First Complete Remission: A Registered Study

[Human Leukocyte Antigen Mismatched Hemopietic Stem Cell Transplants for the Treatment of Leukemia].

Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphocytic Leukemia

Transplantation of HLA-Mismatched Stem Cell Transplantation Without T Cell Depletion for the Treatment of Malignant Hematological Disease.

Haploidentical, Unmanipulated Granulocyte Colony-Stimulating Factor (G-Csf)-primed Peripheral Blood Stem Cell Transplants for Acute Myeloid Leukemia (AML) in Remission: A Single Center Experience.